Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (GB:0JBU)
LSE:0JBU
Holding GB:0JBU?
Track your performance easily
0JBU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.12 - $34.87
Previous Close$21.25
Volume3.97K
Average Volume (3M)4.34K
Market Cap
$2.13B
Enterprise Value$1.55B
Total Cash (Recent Filing)$691.07M
Total Debt (Recent Filing)$106.30M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Oct 31, 2024EPS Estimate
-$1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding101,579,188
10 Day Avg. Volume5,199
30 Day Avg. Volume4,336
Standard Deviation0.28
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.86
Price to Sales (P/S)46.36
Price to Cash Flow (P/CF)-9.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue33.64
Enterprise Value/Gross Profit42.63
Enterprise Value/Ebitda-6.17
Forecast
1Y Price Target
$63.64Price Target Upside199.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Intellia Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the global, pivotal Phase 3 HAELO study of NTLA-2002 in HAE represents a significant step forward for Intellia Therapeutics.
Regulatory OutlookThe removal of uncertainties around an IND approval in the U.S. contributes positively to the stock's outlook.
Safety And EfficacySafety data from Phase II is favorable, with no severe adverse events reported, bolstering confidence in the treatment's profile.
Bears Say
Clinical TrialsDelays or unfavorable outcomes from the ongoing clinical trials could affect the company’s valuation.
Competitive PressureGrowing competition in the transthyretin amyloidosis (ATTR) space has pressured the stock.
Market CompetitionAlnylam's third generation RNAi against ATTR, ALN-TTRsc04, poses another layer of competitive risk for NTLA-2001 as it does not possess off-target editing risk and features similar magnitude of knock-down with annual dosing.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.74% Insiders
21.32% Mutual Funds
0.27% Other Institutional Investors
46.56% Public Companies and
Individual Investors
0JBU FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest share price was $17.12 and its highest was $34.87 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Currently, no data Available
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 12 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 08, 2024. The company reported -$1.52 earnings per share for the quarter, missing the consensus estimate of -$1.217 by -$0.303.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -$1.39.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 101,579,185 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.52 in its last earnings report, missing expectations of -$1.217. Following the earnings report the stock price went up 3.647%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 260M.
---
Intellia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.64 (199.48% Upside)
$63.64 (199.48% Upside)
Blogger Sentiment
Bullish
GB:0JBU Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $38.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.60%
12-Months-Change
Fundamentals
Return on Equity
-49.02%
Trailing 12-Months
Asset Growth
-9.95%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
0JBU Earnings Call
Q2 2024
0:00 / 0:00
---
0JBU Revenue Breakdown
100.00% Collaboration revenue
---
0JBU Stock 12 Month Forecast
Average Price Target
$63.64
▲(199.48% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering 0JBU
1 Year
1 Year Success Rate
13/36 ratings generated profit
1 Year Average Return
+95.39%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 36.11% of your transactions generating a profit, with an average return of +95.39% per trade.
---